Vicore Pharma ($VCRE) Stock Hub: Can Buloxibutid Clear the New IPF Bar When ASPIRE Reads Out in Mid-2027?

01 Bull Case

The constructive case starts with the mechanism. Every approved IPF drug slows the loss of lung function. Buloxibutid targets the angiotensin II type 2 receptor on alveolar epithelial type 2 cells, the lung’s own repair cells, and Vicore argues that this can stabilize or even recover function rather than only slow its decline. In AIR, observed mean FVC rose by 216 mL over 36 weeks; if even a fraction of that survives a placebo arm, it would stand out in a field where 69–130 mL of placebo-adjusted benefit counts as success.

The second pillar is design. Vicore expanded ASPIRE from 270 to 360 planned patients in the fourth quarter of 2025, explicitly to be powered against the efficacy bar set by recent late-stage readouts, and still finished enrolling in April 2026, ahead of its own schedule, with 378 patients randomized across more than 100 sites in 14 countries. The primary endpoint, absolute change in FVC at week 52, is the registrational endpoint in IPF, so a clear positive result would shorten the path to Phase 3.

The third pillar is tolerability: in AIR, diarrhea affected 5.8% of patients and nausea 3.8%, while gastrointestinal side effects are the main reason patients stop current antifibrotics.

Finally, funding and backers: cash is guided into H2 2028, beyond the readout; HealthCap, AP4, HBM, Capital Group, Sanofi and Invus held about 43% of the shares at June 30, 2026; and the Nippon Shinyaku licence for Japan offers up to $275 million in milestones plus royalties.

02 Bear Case And Red Flags

Binary clinical risk dominates. IPF has a long record of encouraging Phase 2 signals that shrank or vanished under placebo control, and AIR was open-label, single-arm and without a concurrent comparator. The headline +216 mL is an observed-data figure; when Vicore imputed missing values assuming an untreated decline of 180 mL over 36 weeks, the mean change fell to +9 mL, and the median observed change was +63 mL.

Benchmark risk compounds it. A statistically significant result may still disappoint if the placebo-adjusted effect is below the 68.8 mL shown by nerandomilast, or well below the 95.6–130.1 mL reported for nebulized treprostinil.

Key red flags to monitor

• Single-asset concentration: the new ATRAG programs are in discovery, with no candidate in IND-enabling studies; buloxibutid in IPF carries essentially all of the value.
• Exclusivity depends on secondary patents: the composition-of-matter patent expired in 2024. Protection rests on formulation patents expected to run to 2041, a method-of-use family to 2042, and orphan and new-chemical-entity exclusivities. Vicore also says it expects to change its current formulation, which the existing families may not fully cover.
• Phase 3 is not funded: the H2 2028 runway covers ASPIRE and Phase 3 readiness work, not a registrational program. The 2026 AGM authorized issues of up to 20% of the share count without preferential rights.
• Rising cost base: H1 2026 operating cash use reached SEK 273.6 million, up from SEK 192.6 million a year earlier.
• Hair loss signal: mild to moderate, generally reversible hair loss affected 19% of AIR patients, the only identified treatment risk.
• ADS mechanics and US tax: primary liquidity sits in Stockholm; the 1:10 ratio confuses price comparisons; Vicore warns that it may be a passive foreign investment company, with possible adverse US tax consequences.

03 Scenario Framework

Descriptive frames, not predictions or recommendations.

Between these poles is another possible outcome: a mixed readout — one dose positive and the other not, a benefit confined to monotherapy patients, a primary hit with an unconvincing secondary, or clean efficacy with a tolerability wrinkle. Such results shift the debate to dose selection, Phase 3 size and cost.

What Would Falsify This Reading

The constructive reading above rests on a handful of assumptions. These are the observations that would undermine it, each checkable against company releases, SEC filings or the ASPIRE registry record.

• ASPIRE shows no placebo-adjusted FVC benefit at week 52. The AIR signal was uncontrolled; a null randomized result would fail to confirm the open-label efficacy signal. Selection, attrition and regression to the mean are possible explanations for uncontrolled improvement, not causes that a null trial would itself prove.
• The effect is real but well below 68.8 mL. That is the nerandomilast benchmark Vicore itself cites; a smaller benefit on top of standard care would weaken the disease-modification argument and the commercial case.
• Topline guidance moves beyond mid-2027. The registry lists May 2027 primary completion; a later date would push the binary event closer to the H2 2028 cash horizon.
• The runway guidance is shortened in the Q3 or year-end report. The H2 2028 guidance depends on future spending and cash-flow assumptions that differ from a flat extrapolation of H1 cash use (see section 12).
• A financing arrives before the readout on weak terms. The 20% issue authorization exists. Assess any financing terms, stated purpose and effect on runway; opportunistic funding before data would not by itself prove that the operating plan had deteriorated.
• Hair loss or another adverse event becomes dose-limiting. Tolerability is central to the differentiation claim.

None of these is a prediction. They are the observations that would make the reading above wrong, listed so that readers can check them rather than take it on trust.

04 Extended Summary

Vicore Pharma Holding AB is a clinical-stage Swedish biotech developing buloxibutid, an oral small-molecule agonist of the angiotensin II type 2 (AT2) receptor, for idiopathic pulmonary fibrosis. The drug holds Orphan Drug designation in the United States, the European Union and Japan, and FDA Fast Track designation granted in January 2025. Its pivotal near-term test is ASPIRE, a global 52-week, randomized, double-blind, placebo-controlled Phase 2b comparing 50 mg and 100 mg twice daily against placebo, which enrolled 378 patients and is guided to report topline results in mid-2027.

The efficacy evidence so far is uncontrolled: the open-label Phase 2a AIR trial reported a mean observed FVC increase of 216 mL at 36 weeks, but +9 mL when missing data were imputed as untreated decline.

Vicore ended June 2026 with SEK 905.6 million of cash and short-term investments and no debt, after H1 operating cash use of SEK 273.6 million. Management guides funding into the second half of 2028; a Phase 3 program would need new capital or a partner.

The investment question is therefore narrow and dated: does a randomized trial confirm a clinically meaningful, tolerable effect large enough to compete with the new benchmarks?

05 Company Overview: What Vicore Pharma Is

Vicore Pharma Holding AB (publ) is headquartered at Kornhamnstorg 53 in Stockholm, with offices in Hørsholm, Denmark, and Cambridge, Massachusetts. The group comprises the parent company, the operating subsidiary Vicore Pharma AB, where research and development is conducted, and Vicore Pharma US Inc. At June 30, 2026 it had 46 employees, 32 of them in R&D, up from 33 a year earlier; manufacturing is outsourced to contract manufacturers in Europe.

The company describes itself as unlocking a new class of drugs, angiotensin II type 2 receptor agonists, which it abbreviates as ATRAGs. Its identity is concentrated: one mechanism, one clinical-stage compound, one lead indication, and a discovery effort on next-generation ATRAGs designed with improved properties and longer patent life.

Revenue is small and not commercial. Q2 2026 net revenue of SEK 2.2 million came from Nippon Shinyaku reimbursing part of the development costs under the Japan licence signed in February 2024.

Vicore has been listed on Nasdaq Stockholm for years and moved from the Small Cap to the Mid Cap segment on January 2, 2026. The US listing in July 2026 changed access, not fundamentals: it added no capital and no new shares. As a foreign private issuer it reports to the SEC through Form 6-K and an annual Form 20-F rather than 10-Qs.

06 The Nasdaq US Listing: A Secondary Listing, Not A US IPO

On July 2, 2026 Vicore’s American Depositary Shares began trading on the Nasdaq Capital Market under VCRE, after the SEC declared its Form 20-F registration effective and Nasdaq approved the listing. The company stated that the listing was completed “without an associated capital raise or issue of new shares” and that it “will receive no proceeds from the listing of its ADSs on Nasdaq.”

The mechanics matter for anyone comparing quotes. Each ADS represents ten ordinary shares, so the ADS price should track roughly ten times the Stockholm share price converted at the SEK/USD rate. Citibank N.A., through Citi Issuer Services, is the depositary. Most liquidity remains on Nasdaq Stockholm, so US trading in VCRE can be thinner and wider-spread than the Swedish line.

The US status also brings specific risk disclosures that ADS holders should read. The 20-F registration warns that Vicore may be a passive foreign investment company for US tax purposes and that ADS holders waive a jury trial for deposit-agreement claims. On August 21, 2026 Vicore also filed a Form S-8 registering shares for its eight incentive programs.

Listing release, July 1, 2026 · SEC · Q2 report · SEC · Form S-8

07 Buloxibutid And AT2 Receptor Agonism: The Scientific Angle

The renin-angiotensin system is best known through its type 1 (AT1) receptor, the receptor blocked by angiotensin receptor blockers; ACE inhibitors instead reduce angiotensin II formation. Stimulating AT1 constricts vessels and promotes inflammation and fibrosis. The type 2 receptor is regarded as the system’s protective arm, expressed in adults mainly after injury and in disease. In the lung it sits mainly on alveolar epithelial type 2 cells (AEC2s), the progenitor cells that renew the alveolar lining and produce surfactant, and Vicore reports that its expression is further increased in IPF lungs. The company’s thesis is that activating AT2, rather than blocking AT1, engages repair biology directly where IPF damage starts.

Buloxibutid, formerly known as C21, is an orally available, low-molecular-weight, selective AT2 receptor agonist. In preclinical work described in Vicore’s Form 20-F registration, it reduced bleomycin-induced death of human AEC2-line cells from 42% to 9% across concentrations of 0.001–0.1 µM, and in ex vivo precision-cut lung slices from IPF patients it raised surfactant proteins SP-B and SP-C by 70% and 120% versus control. In the same slice model it lowered TGF-β1 protein by 61% (at 10 µM) and collagen-1a1 by 44% (at 1 µM).

The vascular side is the second strand: in healthy volunteers infused buloxibutid increased forearm blood flow without lowering systemic blood pressure, and Vicore cites the positive treprostinil data in IPF as support for a mechanism acting on both epithelium and vessels.

Animal and laboratory findings are the basis for testing a drug, not proof that it works in patients. What links the preclinical story to humans is MMP-13: in AIR, plasma levels of this collagen-cleaving enzyme rose by up to about 50% from baseline, and TGF-β1 showed a decreasing trend. Those are biomarker associations, not clinical outcomes.

FDA Fast Track (January 2025) and orphan designations in the US, EU and Japan do not lower the efficacy bar for approval.

SEC · Form 20-F/A, June 9, 2026 · Vicore poster archive

08 AIR: Early, Uncontrolled Evidence And How To Read It

AIR was a multi-center, open-label, single-arm, 36-week Phase 2a trial of buloxibutid 100 mg twice daily in treatment-naive IPF patients confirmed by high-resolution CT. It enrolled 52 patients with a mean age of 67 years, 77% male, and a mean FVC of 75.5% of predicted. Safety was the primary objective; FVC was a secondary endpoint.

The range between +216 mL and +9 mL is the most important fact in the table. The observed-data mean counts only patients who stayed in the trial with measurements, so dropouts — who may be the patients doing worst — fall out of the calculation. The imputed figure assumes every missing patient declined like an untreated patient. Neither is a placebo-adjusted effect. Subgroups are small slices of a 52-patient study.

The synthetic control analysis drew roughly 30,000 random groups of 48 patients from an external IPF database filtered for AIR’s entry criteria, kept the 408 that matched on eight baseline variables, and found that 99.75% of them declined more than the AIR cohort. The company itself notes that such post hoc analyses are less reliable than prespecified randomized endpoints.

Safety and tolerability in AIR

Nine treatment-emergent serious adverse events occurred in five patients (9.6%). Two patients died, one from COVID-19. The investigators judged none related to buloxibutid. Severe adverse events affected 5.8% of patients. Gastrointestinal effects were infrequent: diarrhea 5.8%, nausea 3.8%, vomiting 1.9%. Mild to moderate hair loss, generally reversible, occurred in 19% and is the only identified risk of treatment. Across nine completed trials, 366 participants have received buloxibutid outside ASPIRE, with no treatment-related serious adverse events reported.

AIR justified a randomized trial; it did not establish efficacy.

SEC · Form 20-F/A, Phase 2a AIR section · ATS 2026 presentations

09 ASPIRE Phase 2b: The Central Catalyst

ASPIRE (NCT06588686) is a global, randomized, double-blind, placebo-controlled, parallel-group Phase 2b. Patients are randomized 1:1:1 to buloxibutid 50 mg twice daily, 100 mg twice daily, or placebo for 52 weeks, after up to six weeks of screening and with two to four weeks of follow-up. The registry records the first enrollment on December 9, 2024. In the fourth quarter of 2025 the company raised planned enrollment from 270 to 360, saying recent late-stage readouts had “further clarified emerging efficacy benchmarks” and that a larger sample “enhances the likelihood of a successful readout.” On April 22, 2026 Vicore announced completed enrollment, ahead of plan, with more than 360 patients across over 100 sites in 14 countries, 29 of them in the United States. The registry now lists 378 enrolled.

The primary endpoint is the absolute change from baseline in FVC, in mL, at week 52 — the registrational endpoint in IPF. The key secondary endpoint is a composite: the proportion of patients with an absolute decline of at least 10 points in FVC percent predicted, a respiratory-related hospitalization, or death by week 52.

Eligible patients were at least 40, diagnosed within seven years, with UIP or probable UIP on CT, FVC of at least 50% and DLCO of at least 30% predicted, and either stable on nintedanib or nerandomilast or on no licensed therapy. Pirfenidone is excluded because of drug-interaction risk.

What the ERS 2026 baseline data show

These figures, from a June 16, 2026 database extract presented at ERS on September 7, describe a typical IPF population with relatively preserved lung volume (81.3% predicted FVC) and a shorter time since diagnosis than many trials. The 60/40 split means ASPIRE tests both add-on and monotherapy use, without being described as separately powered for each, so the topline will need subgroup detail.

Timing: Vicore guides topline results for mid-2027. ClinicalTrials.gov, as of October 4, 2026, shows the study active, not recruiting, with primary completion estimated for May 2027 and study completion for June 2027. A positive Phase 2b would lead to a Phase 3 registrational program, not to approval.

ClinicalTrials.gov · ASPIRE · ERS 2026 design and baseline poster · Enrollment release, April 22, 2026 · Year-end report 2025

10 Idiopathic Pulmonary Fibrosis: Market Size And Unmet Need

IPF is a chronic, progressive and ultimately fatal scarring of the lung tissue. Vicore cites about 150,000 people with IPF in the United States and roughly 3 million worldwide, an average life expectancy of three to five years after diagnosis, and a five-year mortality rate of about 80% despite available therapy. The company cites a global IPF market of about $4.2 billion in 2024, projected by third parties to exceed $10 billion by 2030–2033.

The commercial gap is persistence. Vicore states that only about 26% of US patients start treatment, and that high discontinuation leaves an average time on therapy of roughly ten months. Gastrointestinal side effects lead to dose reductions, interruptions and stopping; none of the approved drugs has shown a quality-of-life benefit.

Two cautions apply. First, IPF has humbled many well-financed programs, and a Phase 2b is several years and a Phase 3 away from any approval. Second, the market is changing quickly: the arrival of nerandomilast in 2025 and the treprostinil data give physicians new options, and the next IPF drug will be judged against a moving standard of care rather than against the decade-old pair of nintedanib and pirfenidone.

SEC · Form 20-F/A, market opportunity

11 Competitive Landscape And The Moving Benchmark

After more than a decade with only nintedanib and pirfenidone, IPF is moving again, and Vicore has been open that this shaped ASPIRE. The table summarizes the comparison points as Vicore presents them in its June 2026 registration statement; figures from different trials, populations and durations are not directly comparable.

The numbers explain the ASPIRE expansion. Nerandomilast set a placebo-adjusted bar near 70 mL; treprostinil, an inhaled drug, reported larger effects, but requires nebulization of up to 48 breaths a day and is associated with cough, throat irritation, headache, nausea and flushing. Admilparant, an oral drug from Bristol Myers Squibb, showed a smaller Phase 2 effect over a shorter period and is in Phase 3. Vicore positions buloxibutid as oral, well tolerated and able to preserve rather than slow lung function, a claim not yet tested against placebo.

The practical implication is that ASPIRE will be read relatively. A statistically significant result is necessary but probably not sufficient; the size of the placebo-adjusted effect, its consistency in the 60% of patients on background therapy, the secondary composite, and hair loss rates will all be compared with the datasets above.

SEC · Form 20-F/A, IPF competitive landscape · ERS 2026 release (background therapy)

12 Financial Position, Runway And Burn

Vicore’s Q2 2026 interim report, approved on August 20 and published and furnished to the SEC on August 21, 2026, is the latest full financial statement. It is unaudited and prepared under IFRS in Swedish kronor.

Costs are rising, as expected for a trial in its observation phase. R&D grew 20% year on year in Q2, driven by ASPIRE, and represented 78.0% of operating expenses, down from 87.3% a year earlier. Administrative expenses more than doubled, from SEK 14.1 million to SEK 33.0 million, because of audit, legal and advisory fees for the US registration and listing and a larger administrative team. Net financial income of SEK 7.4 million reflects interest and currency effects on a cash portfolio partly held in foreign currency.

Liquidity. At June 30, 2026 cash and cash equivalents were SEK 428.6 million and short-term investments SEK 477.1 million, a total of SEK 905.6 million, equal to USD 93.0 million at the June 30 rate of SEK 9.73626 per dollar. That compares with SEK 1,059.8 million at March 31 and SEK 1,166.7 million at December 31, 2025. There is no financial debt; total liabilities were SEK 76.2 million, equity SEK 853.6 million, and the equity ratio 91.8%.

Runway. Management states that existing cash funds the expanded ASPIRE trial through topline data in mid-2027 and anticipated operating expenses, including Phase 3 readiness work, into the second half of 2028, on assumptions that may prove wrong. A simple check (Merlintrader arithmetic, not company guidance): H1 2026 operating cash use averaged about SEK 136.8 million per quarter; at that pace SEK 905.6 million covers about 6.6 quarters from June 30, 2026, which lands in the first quarter of 2028. Reaching H2 2028 requires different future cash-flow assumptions from that flat extrapolation. Trial spending can change over time; this arithmetic does not establish the company’s quarterly spending forecast.

What the cash does not cover. Vicore has not published a Phase 3 budget. The company’s 20-F states plainly that it will need substantial additional funding to complete development and potentially commercialize buloxibutid.

SEC · Q2 2026 interim report · Q1 2026 interim report · SEC · Form 20-F/A, liquidity

13 Share Capital, Incentive Plans And Dilution

Vicore has funded itself through repeated equity raises, and the share count has grown accordingly. The November 2025 directed issue brought in about SEK 455.1 million gross (about $48 million) at SEK 9.70 per share; the 46,915,822 new shares equal about 16.7% of the post-issue total. Issue costs were SEK 24.6 million.

Incentive programs. Vicore runs eight share-based programs for employees and board members. At June 30, 2026, 12,991,360 employee stock options and 825,539 board share awards and RSUs had been granted, 13,816,899 instruments in total. The company calculates that exercising all granted instruments would dilute shareholders by up to 4.7%, rising to 8.4% if ungranted options and hedging warrants are included.

Authorization to issue. The Annual General Meeting on May 6, 2026 authorized the board, until the 2027 AGM, to issue new shares with or without preferential rights, up to 20% of the shares and votes at the time of the meeting. On a plain reading it lets the board decide a directed issue of roughly 56 million shares, 20% of the 281,525,593 registered at the AGM date, without a further shareholder vote (Merlintrader calculation).

ADS arithmetic. At one ADS per ten shares, 281,644,509 shares correspond to 28,164,450.9 ADS-equivalents (Merlintrader calculation). That is not the number of ADSs actually issued by the depositary.

SEC · September 30 exhibit · SEC · Q2 report, note 7 · SEC · Form 20-F/A, share capital history

14 Intellectual Property, Exclusivity And The Japan Partnership

Buloxibutid is an older molecule, and its composition-of-matter patent expired in 2024. Vicore’s protection therefore rests on later patent families and on regulatory exclusivities:

• Formulation patents: a peroral dry-mix capsule formulation, with two US patents and grants in Europe, Japan and other territories, and a delayed-release formulation family, both expected to expire in 2041 before any extension.
• Method of use: three US patents covering treatment of IPF with buloxibutid, expected to expire in 2042, with applications pending elsewhere.
• Manufacturing method: applications pending.
• Regulatory exclusivity: orphan designation could bring up to seven years of US market exclusivity and up to ten years in Europe and Japan from approval; new-chemical-entity status could provide five years of US data exclusivity. The June registration statement describes the then-applicable European framework as eight years of data protection followed by two years of market protection, potentially extended for a qualifying new indication; these are distinct from orphan exclusivity and subject to reform and transition rules.

Such patents are generally easier to challenge than a compound patent, and Vicore warns that it expects to change its current formulation and that the change may not be fully covered by existing families. Next-generation ATRAG patent families run to 2040–2042.

Nippon Shinyaku

In February 2024 Vicore granted Nippon Shinyaku exclusive rights to develop and commercialize buloxibutid in IPF in Japan. Vicore received $10 million (SEK 104.2 million) upfront and is eligible for up to $275 million in development and commercial milestones plus tiered royalties up to the low twenties percent of Japanese net sales. Nippon Shinyaku covers part of global development costs, which appear as Vicore’s small reported revenue. Vicore retains all rights outside Japan, so the US and European value — and the decision whether to commercialize alone or with a partner — remains with the company.

SEC · Form 20-F/A, intellectual property and material contracts

15 Ownership: Specialist Funds, Sanofi And The Swedish Base

Vicore’s register is dominated by healthcare specialists and Swedish institutions. The Q2 report, citing Modular Finance data at June 30, 2026, lists the largest holders below; percentages are of the 281,525,593 shares then registered.

The ten largest holders owned about 55.3% of the capital and the top five about 38.4% (Merlintrader sums). HealthCap, AP4 and HBM sat on the nomination committee for the 2026 AGM; Sanofi is the only pharmaceutical company on the list. Several of them, Sanofi included, took part in the November 2025 issue.

Sanofi’s 6.04% stake is worth noting but should not be over-read. A strategic holder is not a partner, and Merlintrader has found no public disclosure of an agreement, option or right of first negotiation with Sanofi. Specialist capital can ease financing after positive data; it offers no protection if ASPIRE fails.

SEC · Q2 report, largest shareholders · SEC · Form 20-F/A, nomination committee

16 Management, Board And The New Chief Scientific Officer

Vicore is led by Chief Executive Officer Ahmed Mousa and Chief Financial Officer Hans Jeppsson. Over 2026 the company rebuilt the layer below them for the late-stage phase. On March 5, 2026 it promoted Bernt van den Blink, MD, PhD, a pulmonologist with more than 25 years in interstitial lung disease, to Chief Medical Officer, succeeding Bertil Lindmark, who became Senior Advisor. Helen Barker, formerly Vice President and Head of CMC, became Chief Technology Officer, and Jimmie Hofman became Chief Business Officer.

On July 6, 2026 Vicore appointed Rob Slack, PhD, FRSB, as Chief Scientific Officer. He came from GSK, where he was Vice President and Head of Respiratory Biology, and was earlier acting CSO at Galecto. He contributed to vilanterol and umeclidinium and led discovery of the inhaled αvβ6 inhibitor GSK3008348 for IPF. He succeeds Johan Raud, MD, PhD, who moved to Senior Advisor. Slack’s stated reason for joining was the mechanism: “The angiotensin II type 2 receptor is one of the most exciting and differentiated mechanisms I have come across in respiratory and fibrotic disease.”

The board is chaired by Hans Schikan and includes Jacob Gunterberg, Yasir Al-Wakeel, Elisabeth Björk, Ann Barbier, Heidi Hunter and, since the May 6, 2026 AGM, Peter Guenter, former CEO of Merck KGaA’s healthcare business and of Almirall and a Sanofi executive for more than twenty years, including a seat on its Executive Committee from 2013.

Insider ownership is small. The 20-F registration lists the ten directors and executive officers as a group with beneficial ownership of 861,821 shares, including options exercisable within 60 days of May 6, 2026, each below 1% — about 0.3% of the share count in total (Merlintrader calculation).

The hires point to preparation for Phase 3 and partnering; pedigree improves execution odds but does not change what ASPIRE will show.

Leadership release, March 5, 2026 · CSO release, July 6, 2026 · Board release, May 7, 2026 · SEC · Form 20-F/A, beneficial ownership

17 Market And Sentiment Snapshot

Reference price. The Marketstack close for VCRE on October 1, 2026 was $9.43 per ADS. Applied to 28,164,450.9 ADS-equivalents (281,644,509 shares at September 30, 2026, divided by ten), that gives about $265.6 million of basic value (Merlintrader calculation). It mixes dates, ignores options and is not a quoted market capitalization. Against June 30 liquidity of about $93.0 million, subtracting that dated liquidity leaves roughly $172.6 million of cash-adjusted basic equity value (Merlintrader arithmetic, mixing dates and currencies). This is neither a precise enterprise value nor a standalone valuation of buloxibutid: subsequent cash use and other assets and liabilities also matter.

Structure data. Finviz data as of October 2, 2026 reported a short ratio of 0.33 days for VCRE, with no float or short-float percentages for the ADS line.

Analyst coverage. Vicore’s investor-relations site lists eight covering firms: ABG Sundal Collier, Cantor, Danske Bank, DNB Carnegie, Guggenheim, Pareto Securities, Stifel and Van Lanschot Kempen. Ratings and targets are not reported here.

Retail sentiment. The StockTwits sentiment score for VCRE was 48/100, labeled “Neutral”, on October 2, 2026, after 59/100 (“Slightly Bullish”) in early September and 40–44 (“Slightly Bearish”) between September 21 and 25. Social-media readings reflect non-professional traders and are not a measure of fundamentals.

Vicore · analyst coverage · SEC · Q2 report, the share

18 Catalysts And What To Watch

The calendar between now and the readout is thin by design: ASPIRE is in its blinded 52-week observation phase, and the company has said its focus is preserving trial quality through database lock. The dated items are financial reports; the decisive item is a window.

What to watch in each step

Q3 report, November 5. Liquidity at September 30 against the SEK 905.6 million June figure, the run-rate of R&D and administrative costs after the listing, and whether management repeats both the mid-2027 topline and the H2 2028 runway language.

Through early 2027. Competitor news for treprostinil, admilparant or nerandomilast in IPF moves the benchmark.

The topline. To read it well, look for: placebo-adjusted FVC change at week 52 for each dose with confidence intervals; results in patients on background therapy and on monotherapy; the key secondary composite; discontinuation and hair loss rates by arm; and any dose-response. A one-line “met the primary endpoint” release without these details would leave most of the questions open.

All September investor events and the ERS presentations have taken place; none involved efficacy data.

SEC · Q2 report, financial calendar · ClinicalTrials.gov · ASPIRE · Conferences · Stifel forum

Update — October 4, 2026

No clinical or financing news has been released since the Q2 report of August 21, 2026. The September 30 notice reported 118,916 new incentive-plan shares, taking the total to 281,644,509. September otherwise brought the ERS ASPIRE baseline poster (September 7) and four investor appearances. The ClinicalTrials.gov record for ASPIRE, as of October 4, 2026, shows the trial active and not recruiting, with 378 enrolled, primary completion estimated for May 2027 and study completion for June 2027.

The next scheduled company event is the Q3 2026 interim report on November 5, 2026, which will update liquidity at September 30, 2026.

SEC · September 30 exhibit · ClinicalTrials.gov · NCT06588686 · ERS 2026 ASPIRE poster

19 Merlintrader Bottom Line

Vicore is a clean, single-question story. The question is whether buloxibutid, an oral AT2 receptor agonist with a genuinely different mechanism from every approved IPF drug, produces a placebo-adjusted lung-function benefit in ASPIRE that is large and consistent enough to compete with nerandomilast and treprostinil, with tolerability good enough to be added to existing therapy. The answer is guided for mid-2027.

What is established: a fully enrolled 378-patient randomized trial on the registrational endpoint; a favorable gastrointestinal profile in AIR; SEK 905.6 million of liquidity at June 30, 2026 with no debt and funding guided into H2 2028; a Japan partner; specialist backers. What is not established: efficacy. AIR’s +216 mL was observed in an uncontrolled study and shrinks to +9 mL under conservative imputation, the core compound patent has expired, and a Phase 3 would need new funding.

Until mid-2027 the measurable items are cash, cost discipline, trial conduct and the competitive benchmark. The analysis is informational and is not a recommendation to buy, sell or hold Vicore shares or ADSs.